


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (canceled)
2. (original) A compound of the Formula II:



II

wherein:

X is C₁₋₁₀ alkylene or C₂₋₁₀ alkenylene;

R_{A1} and R_{B1} are each independently selected from the group consisting of:

hydrogen,
 halogen,
 alkyl,
 alkenyl,
 alkoxy,
 alkylthio, and
 -N(R₉)₂;

or when taken together, R_{A1} and R_{B1} form a fused aryl ring or heteroaryl ring containing one heteroatom selected from the group consisting of N and S, wherein the aryl or heteroaryl ring is unsubstituted or substituted by one or more R groups, or substituted by one R₃ group, or substituted by one R₃ group and one R group;

or when taken together, R_{A1} and R_{B1} form a fused 5 to 7 membered saturated ring, optionally containing one heteroatom selected from the group consisting of N and S, and unsubstituted or substituted by one or more R groups;

R is selected from the group consisting of:

halogen,

hydroxy,
alkyl,
alkenyl,
haloalkyl,
alkoxy,
alkylthio, and
-N(R₉)₂;

R₁ is selected from the group consisting of:

-R₄,
-X'-R₄,
-X'-Y-R₄,
-X'-Y-X'-Y-R₄,
-X'-R₅,
-X''-O-NR_{1a}-Y'-R_{1b}, and
-X''-O-N=C(R₁') (R₁'');

R₂, R'', R_{1a}, R_{1b}, R₁', and R₁'' are independently selected from the group consisting of:


hydrogen,
alkyl,
alkenyl,
aryl,
arylalkylenyl,
heteroaryl,
heteroarylalkylenyl,
heterocyclyl,
heterocyclylalkylenyl, and

alkyl, alkenyl, aryl, arylalkylenyl, heteroaryl, heteroarylalkylenyl, heterocyclyl, or heterocyclylalkylenyl, substituted by one or more substituents selected from the group consisting of:


hydroxy,
alkyl,
haloalkyl,

hydroxyalkyl,
 alkoxy,
 amino,
 dialkylamino,
 $-S(O)_{0-2}$ -alkyl,
 $-S(O)_{0-2}$ -aryl,
 $-NH-S(O)_2$ -alkyl,
 $-NH-S(O)_2$ -aryl,
 haloalkoxy,
 halogen,
 cyano,
 nitro,
 aryl,
 heteroaryl,
 heterocyclyl,
 aryloxy,
 arylalkyleneoxy,
 $-C(O)-O$ -alkyl,
 $-C(O)-N(R_8)_2$,
 $-N(R_8)-C(O)$ -alkyl,
 $-O-(CO)$ -alkyl, and
 $-C(O)$ -alkyl;

or R_2 and R'' and/or R_1' and R_1'' can join together to form a ring system selected from the group consisting of:



wherein the total number of atoms in the ring is 4 to 9, and




wherein the total number of atoms in the ring is 4 to 9;


$$\begin{array}{c} \text{—N—C(R}_6\text{)} \\ | \\ \text{(R}_7\text{)} \end{array} \quad \text{and} \quad \begin{array}{c} \text{—N—S(O)}_2 \\ | \\ \text{(R}_7\text{)} \end{array};$$

- Z-R₄,
- Z-X'-R₄,
- Z-X'-Y-R₄,
- Z-X'-Y-X'-Y-R₄, and
- Z-X'-R₅;

X" is selected from the group consisting of $-\text{CH}(\text{R}_{13})\text{-alkylene-}$ and $-\text{CH}(\text{R}_{13})\text{-alkenylenc-}$, wherein the alkylene and alkenylene are optionally interrupted by one or more $-\text{O}-$ groups;

- S(O)_{0.2}-,
- S(O)₂-N(R₈)-,
- C(R₆)-,
- C(R₆)-O-,
- O-C(R₆)-,
- O-C(O)-O-,
- N(R₈)-Q-,
- C(R₆)-N(R₈)-,
- O-C(R₆)-N(R₈)-,
- C(R₆)-N(OR₉)-,





Y' is selected from the group consisting of:


a bond,

-C(O)-,

-C(S)-,

-S(O)₂-,

-S(O)₂-N(R₈)-,



-C(O)-O-,


-C(O)-N(R₈)-,

-C(S)-N(R₈)-,

-C(O)-N(R₈)-S(O)₂-,

-C(O)-N(R₈)-C(O)-,

-C(S)-N(R₈)-C(O)-,



-C(O)-C(O)-,

-C(O)-C(O)-O-, and


-C(=NH)-N(R₈)-;

Z is a bond or -O-;

R_c and R_d are independently selected from the group consisting of hydrogen, halogen, hydroxy, alkyl, alkenyl, aryl, haloalkyl, alkoxy, alkylthio, and -N(R₉)₂; or R_c and R_d can join to form a fused aryl ring or fused 5-10 membered heteroaryl ring containing one to four heteroatoms;

R₄ is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, mercapto, cyano, aryl, aryloxy, arylalkyleneoxy, heteroaryl, heteroaryloxy, heteroarylalkyleneoxy, heterocyclyl, amino, alkylamino, dialkylamino, (dialkylamino)alkyleneoxy, and in the case of alkyl, alkenyl, alkynyl, and heterocyclyl, oxo;

R₅ is selected from the group consisting of:



R₆ is selected from the group consisting of =O and =S;

R₇ is C₂₋₇ alkylene;

R₈ is selected from the group consisting of hydrogen, C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₁₋₁₀ alkoxy-C₁₋₁₀ alkylenyl, and aryl-C₁₋₁₀ alkylenyl;

R₉ is selected from the group consisting of hydrogen and alkyl;

R₁₀ is C₃₋₈ alkylene;

R₁₁ is C₁₋₆ alkylene or C₂₋₆ alkenylene, wherein the alkylene or alkenylene is optionally interrupted by one heteroatom;

R₁₂ is selected from the group consisting of a bond, C₁₋₅ alkylene, and C₂₋₅ alkenylene, wherein the alkylene or alkenylene is optionally interrupted by one heteroatom;

R₁₃ is selected from the group consisting of hydrogen and alkyl which may be optionally interrupted by one or more -O- groups;

A is selected from the group consisting of $-\text{CH}_2-$, $-\text{O}-$, $-\text{C}(\text{O})-$, $-\text{S}(\text{O})_{0-2}-$, and $-\text{N}(\text{R}_4)-$;

A' is selected from the group consisting of $-\text{O}-$, $-\text{S}(\text{O})_{0-2}-$, $-\text{N}(-\text{Q}-\text{R}_4)-$, and $-\text{CH}_2-$;

Q is selected from the group consisting of a bond, $-\text{C}(\text{R}_6)-$, $-\text{C}(\text{R}_6)-\text{C}(\text{R}_6)-$, $-\text{S}(\text{O})_2-$, $-\text{C}(\text{R}_6)-\text{N}(\text{R}_8)-\text{W}-$, $-\text{S}(\text{O})_2-\text{N}(\text{R}_8)-$, $-\text{C}(\text{R}_6)-\text{O}-$, and $-\text{C}(\text{R}_6)-\text{N}(\text{OR}_9)-$;


V is selected from the group consisting of $-\text{C}(\text{R}_6)-$, $-\text{O}-\text{C}(\text{R}_6)-$, $-\text{N}(\text{R}_8)-\text{C}(\text{R}_6)-$, and $-\text{S}(\text{O})_2-$;

W is selected from the group consisting of a bond, $-\text{C}(\text{O})-$, and $-\text{S}(\text{O})_2-$; and

a and b are independently integers from 1 to 6 with the proviso that $a + b \leq 7$;
or a pharmaceutically acceptable salt thereof.

3. (canceled)

4. (original) A compound of the Formula IIIa:



IIIa

wherein:

X is C_{1-10} alkylene or C_{2-10} alkenylene;

R is selected from the group consisting of:

halogen,

hydroxy,

alkyl,

alkenyl,

haloalkyl,

alkoxy,

alkylthio, and

$-\text{N}(\text{R}_9)_2$;

R_1 is selected from the group consisting of:

- R_4 ,
 - $X'-R_4$,
 - $X'-Y-R_4$,
 - $X'-Y-X'-Y-R_4$,
 - $X'-R_5$,
 - $X''-O-NR_{1a}-Y'-R_{1b}$, and
 - $X''-O-N=C(R_1')(R_1'')$;

R_2 , R'' , R_{1a} , R_{1b} , R_1' , and R_1'' are independently selected from the group consisting of:



hydrogen,
 alkyl,
 alkenyl,
 aryl,
 arylalkylenyl,
 heteroaryl,
 heteroarylalkylenyl,
 heterocyclyl,
 heterocyclylalkylenyl, and

alkyl, alkenyl, aryl, arylalkylenyl, heteroaryl, heteroarylalkylenyl, heterocyclyl, or heterocyclylalkylenyl, substituted by one or more substituents selected from the group consisting of:


hydroxy,
 alkyl,
 haloalkyl,
 hydroxyalkyl,
 alkoxy,
 amino,
 dialkylamino,
 - $S(O)_{0-2}$ -alkyl,
 - $S(O)_{0-2}$ -aryl,
 - $NH-S(O)_2$ -alkyl,

-NH-S(O)₂-aryl,
 haloalkoxy,
 halogen,
 cyano,
 nitro,
 aryl,
 heteroaryl,
 heterocyclyl,
 aryloxy,
 arylalkyleneoxy,
 -C(O)-O-alkyl,
 -C(O)-N(R₈)₂,
 -N(R₈)-C(O)-alkyl,
 -O-(CO)-alkyl, and
 -C(O)-alkyl;

or R₂ and R" and/or R₁' and R₁" can join together to form a ring system selected from the group consisting of:



or R_{1a} and R_{1b} together with the nitrogen atom and Y' to which they are bonded can join to form a ring selected from the group consisting of:



R₃ is selected from the group consisting of:

-Z-R₄,
 -Z-X'-R₄,
 -Z-X'-Y-R₄,

-Z-X'-Y-X'-Y-R₄, and

-Z-X'-R₅;

n is an integer from 0 to 4;

m is 0 or 1; with the proviso that when m is 1, then n is 0 or 1;

X' is selected from the group consisting of alkylene, alkenylene, alkynylene, arylene, heteroarylene, and heterocyclylene wherein the alkylene, alkenylene, and alkynylene groups can be optionally interrupted or terminated by arylene, heteroarylene or heterocyclylene and optionally interrupted by one or more -O- groups;

X" is selected from the group consisting of -CH(R₁₃)-alkylene- and -CH(R₁₃)-alkenylene-, wherein the alkylene and alkenylene are optionally interrupted by one or more -O- groups;

Y is selected from the group consisting of:

-S(O)₀₋₂-,

-S(O)₂-N(R₈)-,

-C(R₆)-,

-C(R₆)-O-,

-O-C(R₆)-,




-O-C(O)-O-,


-N(R₈)-Q-,

-C(R₆)-N(R₈)-,

-O-C(R₆)-N(R₈)-,

-C(R₆)-N(OR₉)-,





Y' is selected from the group consisting of:


a bond,

-C(O)-,

-C(S)-,

-S(O)₂-,

-S(O)₂-N(R₈)-,



-C(O)-O-,


-C(O)-N(R₈)-,

-C(S)-N(R₈)-,

-C(O)-N(R₈)-S(O)₂-,

-C(O)-N(R₈)-C(O)-,

-C(S)-N(R₈)-C(O)-,



-C(O)-C(O)-,

-C(O)-C(O)-O-, and


-C(=NH)-N(R₈)-;

Z is a bond or -O-;

R_c and R_d are independently selected from the group consisting of hydrogen, halogen, hydroxy, alkyl, alkenyl, aryl, haloalkyl, alkoxy, alkylthio, and -N(R₉)₂; or R_c and R_d can join to form a fused aryl ring or fused 5-10 membered heteroaryl ring containing one to four heteroatoms;

R₄ is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, mercapto, cyano, aryl, aryloxy, arylalkyleneoxy, heteroaryl, heteroaryloxy, heteroarylalkyleneoxy, heterocyclyl, amino, alkylamino, dialkylamino, (dialkylamino)alkyleneoxy, and in the case of alkyl, alkenyl, alkynyl, and heterocyclyl, oxo;

R₅ is selected from the group consisting of:



R₆ is selected from the group consisting of =O and =S;

R₇ is C₂₋₇ alkylene;

R₈ is selected from the group consisting of hydrogen, C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₁₋₁₀ alkoxy-C₁₋₁₀ alkylenyl, and aryl-C₁₋₁₀ alkylenyl;

R₉ is selected from the group consisting of hydrogen and alkyl;

R₁₀ is C₃₋₈ alkylene;

R₁₁ is C₁₋₆ alkylene or C₂₋₆ alkenylene, wherein the alkylene or alkenylene is optionally interrupted by one heteroatom;

R₁₂ is selected from the group consisting of a bond, C₁₋₅ alkylene, and C₂₋₅ alkenylene, wherein the alkylene or alkenylene is optionally interrupted by one heteroatom;

R₁₃ is selected from the group consisting of hydrogen and alkyl which may be optionally interrupted by one or more -O- groups;

A is selected from the group consisting of -CH₂-, -O-, -C(O)-, -S(O)₀₋₂-, and -N(R₄)-;

A' is selected from the group consisting of -O-, -S(O)₀₋₂-, -N(-Q-R₄)-, and -CH₂-;


Q is selected from the group consisting of a bond, -C(R₆)-, -C(R₆)-C(R₆)-, -S(O)₂-, -C(R₆)-N(R₈)-W-, -S(O)₂-N(R₈)-, -C(R₆)-O-, and -C(R₆)-N(OR₉)-;

V is selected from the group consisting of $-C(R_6)-$, $-O-C(R_6)-$, $-N(R_8)-C(R_6)-$, and $-S(O)_2-$;

W is selected from the group consisting of a bond, $-C(O)-$, and $-S(O)_2-$; and

a and b are independently integers from 1 to 6 with the proviso that $a + b$ is ≤ 7 ;
or a pharmaceutically acceptable salt thereof.

5. (original) A compound of the Formula IIIa:



IIIa

wherein:


X is C_{1-10} alkylene or C_{2-10} alkenylene;

R is selected from the group consisting of:

halogen,
hydroxy,
alkyl,
alkenyl,
haloalkyl,
alkoxy,
alkylthio, and
 $-N(R_9)_2$;

R_1 is selected from the group consisting of:

$-R_4$,
 $-X'-R_4$,
 $-X'-Y-R_4$,
 $-X'-Y-X'-Y-R_4$,
 $-X'-R_5$,
 $-X''-O-NH-Y'-R_1'$, and



R_2 , R'' , R_1' , and R_1'' are independently selected from the group consisting of:


hydrogen,
alkyl,
alkenyl,
aryl,
arylalkylenyl,
heteroaryl,
heteroarylalkylenyl,
heterocyclyl,
heterocyclylalkylenyl, and

alkyl, alkenyl, aryl, arylalkylenyl, heteroaryl, heteroarylalkylenyl, heterocyclyl, or heterocyclylalkylenyl, substituted by one or more substituents selected from the group consisting of:


hydroxy,
alkyl,
haloalkyl,
hydroxyalkyl,
alkoxy,
dialkylamino,
 $-S(O)_{0-2}$ -alkyl,
 $-S(O)_{0-2}$ -aryl,
 $-NH-S(O)_2$ -alkyl,
 $-NH-S(O)_2$ -aryl,
haloalkoxy,
halogen,
cyano,
nitro,
aryl,
heteroaryl,
heterocyclyl,

aryloxy,
 arylalkyleneoxy,
 -C(O)-O-alkyl,
 -C(O)-N(R₈)₂,
 -N(R₈)-C(O)-alkyl,
 -O-(CO)-alkyl, and
 -C(O)-alkyl;

or R₂ and R" and/or R₁' and R₁" can join together to form a ring system selected from the group consisting of:



wherein the total number of atoms in the ring is 4 to 9, and



wherein the total number of atoms in the ring is 4 to 9;

R₃ is selected from the group consisting of:

-Z-R₄,
 -Z-X'-R₄,
 -Z-X'-Y-R₄,
 -Z-X'-Y-X'-Y-R₄, and
 -Z-X'-R₅;

n is an integer from 0 to 4;

m is 0 or 1; with the proviso that when m is 1, then n is 0 or 1;

X' is selected from the group consisting of alkylene, alkenylene, alkynylene, arylene, heteroarylene, and heterocyclylene wherein the alkylene, alkenylene, and alkynylene groups can be optionally interrupted or terminated by arylene, heteroarylene or heterocyclylene and optionally interrupted by one or more -O- groups;

X" is -CH(R₁₃)-alkylene- or -CH(R₁₃)-alkenylene-;

Y is selected from the group consisting of:

-S(O)₀₋₂-,
 -S(O)₂-N(R₈)-,

-C(R₆)-,

-C(R₆)-O-,

-O-C(R₆)-,


-O-C(O)-O-,

-N(R₈)-Q-,


-C(R₆)-N(R₈)-,

-O-C(R₆)-N(R₈)-,


-C(R₆)-N(OR₉)-,




,




,



,



, and



;

Y' is selected from the group consisting of:


a bond,

-C(O)-,

-C(S)-,









-S(O)₂-,

-S(O)₂-N(R₈)-,



,

-C(O)-O-,




Z is a bond or -O-;

R_c and R_d are independently selected from the group consisting of hydrogen, halogen, hydroxy, alkyl, alkenyl, aryl, haloalkyl, alkoxy, alkylthio, and $-\text{N}(\text{R}_9)_2$; or R_c and R_d can join to form a fused aryl ring or fused 5-10 membered heteroaryl ring containing one to four heteroatoms;

R_4 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, mercapto, cyano, aryl, aryloxy, arylalkyleneoxy, heteroaryl, heteroaryloxy, heteroarylalkyleneoxy, heterocyclyl, amino, alkylamino, dialkylamino, (dialkylamino)alkyleneoxy, and in the case of alkyl, alkenyl, alkynyl, and heterocyclyl, oxo;

R_5 is selected from the group consisting of:



R_6 is selected from the group consisting of =O and =S;

R₇ is C₂₋₇ alkylene;

R₈ is selected from the group consisting of hydrogen, C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₁₋₁₀ alkoxy-C₁₋₁₀ alkylenyl, and aryl-C₁₋₁₀ alkylenyl;

R₉ is selected from the group consisting of hydrogen and alkyl;

R₁₀ is C₃₋₈ alkylene;

R₁₁ is C₁₋₆ alkylene or C₂₋₆ alkenylene, wherein the alkylene or alkenylene is optionally interrupted by one heteroatom;

R₁₂ is selected from the group consisting of a bond, C₁₋₅ alkylene, and C₂₋₅ alkenylene, wherein the alkylene or alkenylene is optionally interrupted by one heteroatom;

R₁₃ is selected from the group consisting of hydrogen and alkyl which may be optionally interrupted by one or more -O- groups;

A is selected from the group consisting of -CH₂-, -O-, -C(O)-, -S(O)₀₋₂-, and -N(R₄)-;

A' is selected from the group consisting of -O-, -S(O)₀₋₂-, -N(-Q-R₄)-, and -CH₂-;

Q is selected from the group consisting of a bond, -C(R₆)-, -C(R₆)-C(R₆)-, -S(O)₂-, -C(R₆)-N(R₈)-W-, -S(O)₂-N(R₈)-, -C(R₆)-O-, and -C(R₆)-N(OR₉)-;


V is selected from the group consisting of -C(R₆)-, -O-C(R₆)-, -N(R₈)-C(R₆)-, and -S(O)₂-;

W is selected from the group consisting of a bond, -C(O)-, and -S(O)₂-; and

a and b are independently integers from 1 to 6 with the proviso that a + b is ≤ 7; or a pharmaceutically acceptable salt thereof.

6. (canceled)

7. (currently amended) The compound of claim 2 wherein the A-compound is of the Formula IVa:



IVa

wherein:

X is C₁₋₁₀ alkylene or C₂₋₁₀ alkenylene;

R is selected from the group consisting of:

halogen,
hydroxy,
alkyl,
alkenyl,
haloalkyl,
alkoxy,
alkylthio, and
-N(R₉)₂;

n is an integer from 0 to 4;

R₁ is selected from the group consisting of:

-R₄,
-X'-R₄,
-X'-Y-R₄,
-X'-Y-X'-Y-R₄,
-X'-R₅,
-X''-O-NR_{1a}-Y'-R_{1b}, and
-X''-O-N=C(R_{1'})(R_{1''});


R₂, R'', R_{1a}, R_{1b}, R_{1'}, and R_{1''} are independently selected from the group consisting of:

hydrogen,
alkyl,
alkenyl,
aryl,
arylalkylenyl,
heteroaryl,
heteroarylalkylenyl,
heterocyclyl,
heterocyclylalkylenyl, and


alkyl, alkenyl, aryl, arylalkylenyl, heteroaryl, heteroarylalkylenyl, heterocyclyl, or heterocyclalkylenyl, substituted by one or more substituents selected from the group consisting of:

hydroxy,
alkyl,
haloalkyl,
hydroxyalkyl,
alkoxy,
amino,
dialkylamino,
-S(O)₀₋₂-alkyl,
-S(O)₀₋₂-aryl,
-NH-S(O)₂-alkyl,
-NH-S(O)₂-aryl,
haloalkoxy,
halogen,
cyano,
nitro,
aryl,
heteroaryl,
heterocyclyl,
aryloxy,
arylalkyleneoxy,
-C(O)-O-alkyl,
-C(O)-N(R₈)₂,
-N(R₈)-C(O)-alkyl,
-O-(CO)-alkyl, and
-C(O)-alkyl;

or R₂ and R'' and/or R₁' and R₁'' can join together to form a ring system selected from the group consisting of:




wherein the total number of atoms in the ring is 4 to 9, and



wherein the total number of atoms in the ring is 4 to 9;



or R_{1a} and R_{1b} together with the nitrogen atom and Y' to which they are bonded can join to form a ring selected from the group consisting of:




X' is selected from the group consisting of alkylene, alkenylene, alkynylene, arylene, heteroarylene, and heterocyclylene wherein the alkylene, alkenylene, and alkynylene groups can be optionally interrupted or terminated by arylene, heteroarylene or heterocyclylene and optionally interrupted by one or more -O- groups;

X'' is selected from the group consisting of -CH(R₁₃)-alkylene- and -CH(R₁₃)-alkenylene-, wherein the alkylene and alkenylene are optionally interrupted by one or more -O- groups;

Y is selected from the group consisting of:





Y' is selected from the group consisting of:


a bond,

-C(O)-,

-C(S)-,

-S(O)₂-,

-S(O)₂-N(R₈)-,



-C(O)-O-,


-C(O)-N(R₈)-,

-C(S)-N(R₈)-,

-C(O)-N(R₈)-S(O)₂-,

-C(O)-N(R₈)-C(O)-,

-C(S)-N(R₈)-C(O)-,



-C(O)-C(O)-,


-C(O)-C(O)-O-, and

-C(=NH)-N(R₈)-;

R_c and R_d are independently selected from the group consisting of hydrogen, halogen, hydroxy, alkyl, alkenyl, aryl, haloalkyl, alkoxy, alkylthio, and $-N(R_9)_2$; or R_c and R_d can join to form a fused aryl ring or fused 5-10 membered heteroaryl ring containing one to four heteroatoms;

R_4 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, mercapto, cyano, aryl, aryloxy, arylalkyleneoxy, heteroaryl, heteroaryloxy, heteroarylalkyleneoxy, heterocyclyl, amino, alkylamino, dialkylamino, (dialkylamino)alkyleneoxy, and in the case of alkyl, alkenyl, alkynyl, and heterocyclyl, oxo;

R_5 is selected from the group consisting of:



R_6 is selected from the group consisting of $=O$ and $=S$;

R_7 is C_{2-7} alkylene;

R_8 is selected from the group consisting of hydrogen, C_{1-10} alkyl, C_{2-10} alkenyl, C_{1-10} alkoxy- C_{1-10} alkylenyl, and aryl- C_{1-10} alkylenyl;

R_9 is selected from the group consisting of hydrogen and alkyl;

R_{10} is C_{3-8} alkylene;

R_{11} is C_{1-6} alkylene or C_{2-6} alkenylene, wherein the alkylene or alkenylene is optionally interrupted by one heteroatom;

R_{12} is selected from the group consisting of a bond, C_{1-5} alkylene, and C_{2-5} alkenylene, wherein the alkylene or alkenylene is optionally interrupted by one heteroatom;

R_{13} is selected from the group consisting of hydrogen and alkyl which may be optionally interrupted by one or more $-O-$ groups;

A is selected from the group consisting of $-\text{CH}_2-$, $-\text{O}-$, $-\text{C(O)}-$, $-\text{S(O)}_{0-2}-$, and

$-N(R_4)-$;

A' is selected from the group consisting of $-O-$, $-S(O)_{0-2}-$, $-N(-Q-R_4)-$, and $-CH_2-$;


Q is selected from the group consisting of a bond, $-C(R_6)-$, $-C(R_6)-C(R_6)-$, $-S(O)_2-$, $-C(R_6)-N(R_8)-W-$, $-S(O)_2-N(R_8)-$, $-C(R_6)-O-$, and $-C(R_6)-N(OR_9)-$;

V is selected from the group consisting of $-C(R_6)-$, $-O-C(R_6)-$, $-N(R_8)-C(R_6)-$, and $-S(O)_2-$;

W is selected from the group consisting of a bond, $-C(O)-$, and $-S(O)_2-$; and

a and b are independently integers from 1 to 6 with the proviso that $a + b$ is ≤ 7 ;
or a pharmaceutically acceptable salt thereof.

8. (original) A compound of the Formula IVa:



IVa

wherein:

X is C_{1-10} alkylene or C_{2-10} alkenylene;

R is selected from the group consisting of:

halogen,

hydroxy,

alkyl,

alkenyl,

haloalkyl,

alkoxy,

alkylthio, and

$-N(R_9)_2$;

n is an integer from 0 to 4;

R₁ is selected from the group consisting of:

$-R_4$,

$-X'-R_4$,
 $-X'-Y-R_4$,
 $-X'-Y-X'-Y-R_4$,
 $-X'-R_5$,
 $-X''-O-NH-Y'-R_1'$, and
 $-X''-O-N=C(R_1')(R_1'')$;

R_2 , R'' , R_1' , and R_1'' are independently selected from the group consisting of:


hydrogen,
 alkyl,
 alkenyl,
 aryl,
 arylalkylenyl,
 heteroaryl,
 heteroarylalkylenyl,
 heterocyclyl,
 heterocyclylalkylenyl, and

alkyl, alkenyl, aryl, arylalkylenyl, heteroaryl, heteroarylalkylenyl, heterocyclyl, or heterocyclylalkylenyl, substituted by one or more substituents selected from the group consisting of:


hydroxy,
 alkyl,
 haloalkyl,
 hydroxyalkyl,
 alkoxy,
 dialkylamino,
 $-S(O)_{0-2}$ -alkyl,
 $-S(O)_{0-2}$ -aryl,
 $-NH-S(O)_2$ -alkyl,
 $-NH-S(O)_2$ -aryl,
 haloalkoxy,
 halogen,

cyano,
 nitro,
 aryl,
 heteroaryl,
 heterocyclyl,
 aryloxy,
 arylalkyleneoxy,
 -C(O)-O-alkyl,
 -C(O)-N(R₈)₂,
 -N(R₈)-C(O)-alkyl,
 -O-(CO)-alkyl, and
 -C(O)-alkyl;

or R₂ and R'' and/or R₁' and R₁'' can join together to form a ring system selected from the group consisting of:



wherein the total number of atoms in the ring is 4 to 9, and



wherein the total number of atoms in the ring is 4 to 9;

X' is selected from the group consisting of alkylene, alkenylene, alkynylene, arylene, heteroarylene, and heterocyclylene wherein the alkylene, alkenylene, and alkynylene groups can be optionally interrupted or terminated by arylene, heteroarylene or heterocyclylene and optionally interrupted by one or more -O- groups;

X'' is -CH(R₁₃)-alkylene- or -CH(R₁₃)-alkenylene-;

Y is selected from the group consisting of:

-S(O)₀₋₂-,
 -S(O)₂-N(R₈)-,
 -C(R₆)-,
 -C(R₆)-O-,
 -O-C(R₆)-,


-O-C(O)-O-,

-N(R₈)-Q-,


-C(R₆)-N(R₈)-,

-O-C(R₆)-N(R₈)-,


-C(R₆)-N(OR₉)-,




,




,



,



, and



;

Y' is selected from the group consisting of:


a bond,

-C(O)-,

-C(S)-,

-S(O)₂-,

-S(O)₂-N(R₈)-,







,

-C(O)-O-,

-C(O)-N(R₈)-,

-C(S)-N(R₈)-,


-C(O)-N(R₈)-S(O)₂-,



R_c and R_d are independently selected from the group consisting of hydrogen, halogen, hydroxy, alkyl, alkenyl, aryl, haloalkyl, alkoxy, alkylthio, and $-\text{N}(\text{R}_9)_2$; or R_c and R_d can join to form a fused aryl ring or fused 5-10 membered heteroaryl ring containing one to four heteroatoms;

R_4 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, mercapto, cyano, aryl, aryloxy, arylalkyleneoxy, heteroaryl, heteroaryloxy, heteroarylalkyleneoxy, heterocyclyl, amino, alkylamino, dialkylamino, (dialkylamino)alkyleneoxy, and in the case of alkyl, alkenyl, alkynyl, and heterocyclyl, oxo;

R_5 is selected from the group consisting of:



R_6 is selected from the group consisting of $=\text{O}$ and $=\text{S}$;

R_7 is C_{2-7} alkylene;

R_8 is selected from the group consisting of hydrogen, C_{1-10} alkyl, C_{2-10} alkenyl, C_{1-10} alkoxy- C_{1-10} alkyl, and aryl- C_{1-10} alkyl;

R_9 is selected from the group consisting of hydrogen and alkyl;

R_{10} is C_{3-8} alkylene;

R_{11} is C_{1-6} alkylene or C_{2-6} alkenylene, wherein the alkylene or alkenylene is optionally interrupted by one heteroatom;

R_{12} is selected from the group consisting of a bond, C_{1-5} alkylene, and C_{2-5} alkenylene, wherein the alkylene or alkenylene is optionally interrupted by one heteroatom;

R_{13} is selected from the group consisting of hydrogen and alkyl which may be optionally interrupted by one or more -O- groups;

A is selected from the group consisting of $-CH_2-$, -O-, $-C(O)-$, $-S(O)_{0-2}-$, and $-N(R_4)-$;

A' is selected from the group consisting of -O-, $-S(O)_{0-2}-$, $-N(-Q-R_4)-$, and $-CH_2-$;


Q is selected from the group consisting of a bond, $-C(R_6)-$, $-C(R_6)-C(R_6)-$, $-S(O)_2-$, $-C(R_6)-N(R_8)-W-$, $-S(O)_2-N(R_8)-$, $-C(R_6)-O-$, and $-C(R_6)-N(OR_9)-$;

V is selected from the group consisting of $-C(R_6)-$, $-O-C(R_6)-$, $-N(R_8)-C(R_6)-$, and $-S(O)_2-$;

W is selected from the group consisting of a bond, $-C(O)-$, and $-S(O)_2-$; and

a and b are independently integers from 1 to 6 with the proviso that $a + b$ is ≤ 7 ; or a pharmaceutically acceptable salt thereof.

9. (currently amended) The compound of claim 2 wherein the A-compound is of the Formula V:



wherein:

X is C_{1-10} alkylene or C_{2-10} alkenylene;

R is selected from the group consisting of:

halogen,

hydroxy,

alkyl,
 alkenyl,
 haloalkyl,
 alkoxy,
 alkylthio, and
 $-N(R_9)_2$;

R_1 is selected from the group consisting of:

$-R_4$,
 $-X'-R_4$,
 $-X'-Y-R_4$,
 $-X'-Y-X'-Y-R_4$,
 $-X'-R_5$,
 $-X''-O-NR_{1a}-Y'-R_{1b}$, and
 $-X''-O-N=C(R_1')(R_1'')$;

R_2 , R'' , R_{1a} , R_{1b} , R_1' , and R_1'' are independently selected from the group consisting of:


hydrogen,
 alkyl,
 alkenyl,
 aryl,
 arylalkylenyl,
 heteroaryl,
 heteroarylalkylenyl,
 heterocyclyl,
 heterocyclylalkylenyl, and

alkyl, alkenyl, aryl, arylalkylenyl, heteroaryl, heteroarylalkylenyl, heterocyclyl, or heterocyclylalkylenyl, substituted by one or more substituents selected from the group consisting of:


hydroxy,
 alkyl,
 haloalkyl,
 hydroxyalkyl,

alkoxy,
 amino,
 dialkylamino,
 $-S(O)_{0-2}$ -alkyl,
 $-S(O)_{0-2}$ -aryl,
 $-NH-S(O)_2$ -alkyl,
 $-NH-S(O)_2$ -aryl,
 haloalkoxy,
 halogen,
 cyano,
 nitro,
 aryl,
 heteroaryl,
 heterocyclyl,
 aryloxy,
 arylalkyleneoxy,
 $-C(O)-O$ -alkyl,
 $-C(O)-N(R_8)_2$,
 $-N(R_8)-C(O)$ -alkyl,
 $-O-(CO)$ -alkyl, and
 $-C(O)$ -alkyl;

or R_2 and R'' and/or R_1' and R_1'' can join together to form a ring system selected from the group consisting of:




wherein the total number of atoms in the ring is 4 to 9, and



wherein the total number of atoms in the ring is 4 to 9;

or R_{1a} and R_{1b} together with the nitrogen atom and Y' to which they are bonded can join to form a ring selected from the group consisting of:



R_3 is selected from the group consisting of:

-Z-R₄,

$$-Z-X'-R_4,$$
$$-Z-X'-Y-R_4,$$

-Z-X'-Y-X'-Y-R₄, and

$$-Z-X'-R_5;$$

p is an integer from 0 to 3;

m is 0 or 1, with the proviso that when m is 1, p is 0 or 1;

X' is selected from the group consisting of alkylene, alkenylene, alkynylene, arylene, heteroarylene, and heterocyclylene wherein the alkylene, alkenylene, and alkynylene groups can be optionally interrupted or terminated by arylene, heteroarylene or heterocyclylene and optionally interrupted by one or more -O- groups;


X" is selected from the group consisting of $-\text{CH}(\text{R}_{13})\text{-alkylene-}$ and $-\text{CH}(\text{R}_{13})\text{-alkenylenc-}$, wherein the alkylene and alkenylene are optionally interrupted by one or more $-\text{O}-$ groups;


Y is selected from the group consisting of:

-S(O)₀₋₂-,

$$-\text{S}(\text{O})_2-\text{N}(\text{R}_8)-,$$
$$-\text{C}(\text{R}_6)-,$$
$$-\text{C}(\text{R}_6)-\text{O}-,$$
$$-\text{O}-\text{C}(\text{R}_6)-,$$
$$-\text{O}-\text{C}(\text{O})-\text{O}-,$$

-N(R₈)-Q-

$$-\text{C}(\text{R}_6)-\text{N}(\text{R}_8)-,$$
$$-\text{O}-\text{C}(\text{R}_6)-\text{N}(\text{R}_8)-,$$
$$-\text{C}(\text{R}_6)-\text{N}(\text{OR}_9)-,$$




Y' is selected from the group consisting of:


a bond,

-C(O)-,

-C(S)-,

-S(O)₂-,

-S(O)₂-N(R₈)-,



-C(O)-O-,


-C(O)-N(R₈)-,

-C(S)-N(R₈)-,

-C(O)-N(R₈)-S(O)₂-,

-C(O)-N(R₈)-C(O)-,

-C(S)-N(R₈)-C(O)-,



-C(O)-C(O)-,

-C(O)-C(O)-O-, and


-C(=NH)-N(R₈)-;

Z is a bond or -O-;

R_c and R_d are independently selected from the group consisting of hydrogen, halogen, hydroxy, alkyl, alkenyl, aryl, haloalkyl, alkoxy, alkylthio, and -N(R₉)₂; or R_c and R_d can join to form a fused aryl ring or fused 5-10 membered heteroaryl ring containing one to four heteroatoms;

R₄ is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, mercapto, cyano, aryl, aryloxy, arylalkyleneoxy, heteroaryl, heteroaryloxy, heteroarylalkyleneoxy, heterocyclyl, amino, alkylamino, dialkylamino, (dialkylamino)alkyleneoxy, and in the case of alkyl, alkenyl, alkynyl, and heterocyclyl, oxo;

R₅ is selected from the group consisting of:



R₆ is selected from the group consisting of =O and =S;

R₇ is C₂₋₇ alkylene;

R₈ is selected from the group consisting of hydrogen, C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₁₋₁₀ alkoxy-C₁₋₁₀ alkylene, and aryl-C₁₋₁₀ alkylene;

R₉ is selected from the group consisting of hydrogen and alkyl;

R₁₀ is C₃₋₈ alkylene;

R₁₁ is C₁₋₆ alkylene or C₂₋₆ alkenylene, wherein the alkylene or alkenylene is optionally interrupted by one heteroatom;

R₁₂ is selected from the group consisting of a bond, C₁₋₅ alkylene, and C₂₋₅ alkenylene, wherein the alkylene or alkenylene is optionally interrupted by one heteroatom;

R₁₃ is selected from the group consisting of hydrogen and alkyl which may be optionally interrupted by one or more -O- groups;

A is selected from the group consisting of $-\text{CH}_2-$, $-\text{O}-$, $-\text{C}(\text{O})-$, $-\text{S}(\text{O})_{0-2}-$, and $-\text{N}(\text{R}_4)-$;

A' is selected from the group consisting of $-\text{O}-$, $-\text{S}(\text{O})_{0-2}-$, $-\text{N}(-\text{Q}-\text{R}_4)-$, and $-\text{CH}_2-$;


Q is selected from the group consisting of a bond, $-\text{C}(\text{R}_6)-$, $-\text{C}(\text{R}_6)-\text{C}(\text{R}_6)-$, $-\text{S}(\text{O})_2-$, $-\text{C}(\text{R}_6)-\text{N}(\text{R}_8)-\text{W}-$, $-\text{S}(\text{O})_2-\text{N}(\text{R}_8)-$, $-\text{C}(\text{R}_6)-\text{O}-$, and $-\text{C}(\text{R}_6)-\text{N}(\text{OR}_9)-$;

V is selected from the group consisting of $-\text{C}(\text{R}_6)-$, $-\text{O}-\text{C}(\text{R}_6)-$, $-\text{N}(\text{R}_8)-\text{C}(\text{R}_6)-$, and $-\text{S}(\text{O})_2-$;

W is selected from the group consisting of a bond, $-\text{C}(\text{O})-$, and $-\text{S}(\text{O})_2-$; and

a and b are independently integers from 1 to 6 with the proviso that $a + b \leq 7$;
or a pharmaceutically acceptable salt thereof.

10. (currently amended) The compound of claim 2 wherein the A-compound is of the Formula VI:



VI

wherein:

X is C_{1-10} alkylene or C_{2-10} alkenylene;

$\text{R}_{\text{A}2}$ and $\text{R}_{\text{B}2}$ are each independently selected from the group consisting of:

hydrogen,

halogen,

alkyl,

alkenyl,

alkoxy,

alkylthio, and

$-\text{N}(\text{R}_9)_2$;

R_1 is selected from the group consisting of:

$-\text{R}_4$,

$-X'-R_4$,
 $-X'-Y-R_4$,
 $-X'-Y-X'-Y-R_4$,
 $-X'-R_5$,
 $-X''-O-NR_{1a}-Y'-R_{1b}$, and
 $-X''-O-N=C(R_1')(R_1'')$;

R_2 , R'' , R_{1a} , R_{1b} , R_1' , and R_1'' are independently selected from the group consisting of:


hydrogen,
 alkyl,
 alkenyl,
 aryl,
 arylalkylenyl,
 heteroaryl,
 heteroarylalkylenyl,
 heterocyclyl,
 heterocyclylalkylenyl, and

alkyl, alkenyl, aryl, arylalkylenyl, heteroaryl, heteroarylalkylenyl, heterocyclyl, or heterocyclylalkylenyl, substituted by one or more substituents selected from the group consisting of:


hydroxy,
 alkyl,
 haloalkyl,
 hydroxyalkyl,
 alkoxy,
 amino,
 dialkylamino,
 $-S(O)_{0-2}$ -alkyl,
 $-S(O)_{0-2}$ -aryl,
 $-NH-S(O)_2$ -alkyl,
 $-NH-S(O)_2$ -aryl,
 haloalkoxy,

halogen,
 cyano,
 nitro,
 aryl,
 heteroaryl,
 heterocyclyl,
 aryloxy,
 arylalkyleneoxy,
 -C(O)-O-alkyl,
 -C(O)-N(R₈)₂,
 -N(R₈)-C(O)-alkyl,
 -O-(CO)-alkyl, and
 -C(O)-alkyl;

or R₂ and R" and/or R₁' and R₁" can join together to form a ring system selected from the group consisting of:




wherein the total number of atoms in the ring is 4 to 9, and



wherein the total number of atoms in the ring is 4 to 9;

or R_{1a} and R_{1b} together with the nitrogen atom and Y' to which they are bonded can join to form a ring selected from the group consisting of:















X' is selected from the group consisting of alkylene, alkenylene, alkynylene, arylene, heteroarylene, and heterocyclylene wherein the alkylene, alkenylene, and alkynylene groups can be optionally interrupted or terminated by arylene, heteroarylene or heterocyclylene and optionally interrupted by one or more -O- groups;

X" is selected from the group consisting of -CH(R₁₃)-alkylene- and


-CH(R₁₃)-alkenylene-, wherein the alkylene and alkenylene are optionally interrupted by one or more -O- groups;










Y is selected from the group consisting of:



Y' is selected from the group consisting of:

a bond,






R_c and R_d are independently selected from the group consisting of hydrogen, halogen, hydroxy, alkyl, alkenyl, aryl, haloalkyl, alkoxy, alkylthio, and $-\text{N}(\text{R}_9)_2$; or R_c and R_d can join to form a fused aryl ring or fused 5-10 membered heteroaryl ring containing one to four heteroatoms;

R_4 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, mercapto, cyano, aryl, aryloxy, arylalkyleneoxy, heteroaryl, heteroaryloxy, heteroarylalkyleneoxy, heterocyclyl, amino, alkylamino, dialkylamino, (dialkylamino)alkyleneoxy, and in the case of alkyl, alkenyl, alkynyl, and heterocyclyl, oxo;

R_5 is selected from the group consisting of:



R₆ is selected from the group consisting of =O and =S;

R₇ is C₂₋₇ alkylene;

R₈ is selected from the group consisting of hydrogen, C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₁₋₁₀ alkoxy-C₁₋₁₀ alkylenyl, and aryl-C₁₋₁₀ alkylenyl;

R₉ is selected from the group consisting of hydrogen and alkyl;

R₁₀ is C₃₋₈ alkylene;

R₁₁ is C₁₋₆ alkylene or C₂₋₆ alkenylene, wherein the alkylene or alkenylene is optionally interrupted by one heteroatom;

R₁₂ is selected from the group consisting of a bond, C₁₋₅ alkylene, and C₂₋₅ alkenylene, wherein the alkylene or alkenylene is optionally interrupted by one heteroatom;

R₁₃ is selected from the group consisting of hydrogen and alkyl which may be optionally interrupted by one or more -O- groups;

A is selected from the group consisting of -CH₂-, -O-, -C(O)-, -S(O)₀₋₂-, and -N(R₄)-;

A' is selected from the group consisting of -O-, -S(O)₀₋₂-, -N(-Q-R₄)-, and -CH₂-;

Q is selected from the group consisting of a bond, -C(R₆)-, -C(R₆)-C(R₆)-, -S(O)₂-, -C(R₆)-N(R₈)-W-, -S(O)₂-N(R₈)-, -C(R₆)-O-, and -C(R₆)-N(OR₉)-;

V is selected from the group consisting of -C(R₆)-, -O-C(R₆)-, -N(R₈)-C(R₆)-, and -S(O)₂-;

W is selected from the group consisting of a bond, -C(O)-, and -S(O)₂-; and

a and b are independently integers from 1 to 6 with the proviso that a + b is ≤ 7; or a pharmaceutically acceptable salt thereof.

11-15 (canceled)

16. (currently amended) The compound or salt of ~~any one of claims 3 through 8, or claim 15 as dependent on claim 4 or claim 5, claim 7~~ wherein n is 0.

17. (currently amended) The compound or salt of ~~any one of claims 4 or 5, or claim 16 as dependent on any of claims 4, 5, or 15~~ claim 4 wherein n and m are 0.


18. (canceled)

19. (currently amended) The compound or salt of claim 9 ~~or claim 15 as dependent on claim 9 or claim 14~~ wherein m and p are 0.


20. (original) The compound or salt of claim 10 wherein R_{A2} and R_{B2} are each methyl.

21-22 (canceled)


23. (currently amended) The compound or salt of ~~any one of claims 2, 4, 5, 7 through 15, claims 17 through 20, or claim 16 as dependent on any one of claims 4, 5, 7, 8, or 15~~, claim 2 wherein R_1 is selected from the group consisting of alkyl, arylalkylenyl, aryloxyalkylenyl, hydroxyalkyl, alkylsulfonylalkylenyl, $-X'-Y-R_4$, and $-X'-R_5$; wherein X' is alkylene; Y is $-N(R_8)-C(O)-$, $-N(R_8)-S(O)_2-$, $-N(R_8)-S(O)_2-N(R_8)-$, $-N(R_8)-C(O)-N(R_8)-$, $-N(R_8)-C(O)-N(R_8)-C(O)-$,



; R_4 is hydrogen, alkyl, alkenyl, aryl, or heteroaryl, wherein alkyl and alkenyl are optionally substituted by aryl or aryloxy and wherein aryl is optionally substituted by one or more substituents selected from the group consisting of alkyl, alkoxy, cyano, and halogen; and R_5 is



24. (original) The compound or salt of claim 23 wherein R_1 is 2-methylpropyl, 2-hydroxy-2-methylpropyl, or $-X'-Y-R_4$; X' is ethylene, propylene, or butylene; Y is $-NH-C(O)-$, $-NH-S(O)_2-$, $-NH-S(O)_2-N(R_8)-$, $-NH-C(O)-N(R_8)-$, $-NH-C(O)-NH-C(O)-$, or



25. (canceled)

26. (currently amended) The compound or salt of ~~any one of claims 1 through 10, 14 through 22, 24, or 25, or claim 23 as dependent on any one of claims 2, 4, 5, 7 through 10 or 14 through 20,~~ claim 2 wherein at least one of R" or R₂ is selected from the group consisting of alkyl, alkenyl, aryl, arylalkylenyl, heteroaryl, heteroarylalkylenyl, heterocyclyl, and heterocyclalkylenyl, wherein the alkyl, alkenyl, aryl, arylalkylenyl, heteroaryl, heteroarylalkylenyl, heterocyclyl, and heterocyclalkylenyl are optionally substituted.


27-31 (canceled)

32. (currently amended) The compound or salt of ~~any one of claims 1 through 10, 14 through 22, or 24, or claim 23 as dependent on any one of claims 2, 4, 5, 7 through 10 or 14 through 20,~~ claim 2 wherein R₂ and R" are independently C₁₋₁₀ alkyl.

33. (original) The compound or salt of claim 32 wherein R₂ and R" are each methyl.

34-35 (canceled)

36. (currently amended) The compound or salt of claim ~~35~~ 2 wherein R₂ and R" join together to form the ring system is



, wherein R₁₁ is C₁₋₂ alkylene; A' is -CH₂-, -O-, or -N(-Q-R₄)-; Q is a bond or -C(O)-; and R₄ is alkyl or arylalkylenyl.

37. (currently amended) The compound or salt of ~~any one of claims 1 through 36~~ claim 2 wherein X is C₁₋₄ alkylene.

38. (original) The compound or salt of claim 37 wherein X is methylene.

39. (currently amended) The compound or salt of ~~any one of claims 2, 4, 5, 7 through 10, 14, 15, or 17 through 20, or claim 16 as dependent on any one of claims 4, 5, 7, 8, or 15, claim 2~~ wherein X is C₁₋₄ alkylene; R₂ is C₁₋₄ alkyl; R" is hydrogen or C₁₋₄ alkyl; and R₁ is C₁₋₆ alkyl or hydroxy-C₁₋₆ alkyl; or X is C₁₋₄ alkylene; R" is C₁₋₄ alkyl; R₂ is hydrogen or C₁₋₄ alkyl; and R₁ is C₁₋₆ alkyl or hydroxy-C₁₋₆ alkyl.

40-41 (canceled)

42. (currently amended) The compound or salt of ~~any one of claims 39, 40, or 41~~ claim 2 wherein X is methylene; R" and R₂ are methyl; and R₁ is 2-methylpropyl or 2-hydroxy-2-methylpropyl.

43. (currently amended) A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of ~~any one of claims 1 through 42~~ claim 2 in combination with a pharmaceutically acceptable carrier.

44. (currently amended) A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound or salt of ~~any one of claims 1 through 42~~ claim 2 to the animal.


45. (currently amended) A method of treating a viral disease in an animal in need thereof comprising administering a therapeutically effective amount of a compound or salt of ~~any one of claims 1 through 42~~ claim 2 to the animal.

46. (currently amended) A method of treating a neoplastic disease in an animal in need thereof comprising administering a therapeutically effective amount of a compound or salt of ~~any one of claims 1 through 42~~ claim 2 to the animal.

47. (canceled)

52. (new) The compound or salt of claim 51 wherein R_2 and R'' are each methyl.

53. (new) The compound or salt of claim 4 wherein R_2 and R'' join together to form the ring system



54. (new) The compound or salt of claim 4 wherein X is C_{1-4} alkylene.


55. (new) The compound or salt of claim 54 wherein X is methylene.

56. (new) The compound or salt of claim 4 wherein X is C_{1-4} alkylene; R_2 is C_{1-4} alkyl; R'' is hydrogen or C_{1-4} alkyl; and R_1 is C_{1-6} alkyl or hydroxy- C_{1-6} alkyl; or X is C_{1-4} alkylene; R'' is C_{1-4} alkyl; R_2 is hydrogen or C_{1-4} alkyl; and R_1 is C_{1-6} alkyl or hydroxy- C_{1-6} alkyl.


57. (new) A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 4 in combination with a pharmaceutically acceptable carrier.

58. (new) A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound or salt of claim 4 to the animal.

59. (new) The compound or salt of claim 7 wherein R_1 is selected from the group consisting of alkyl, arylalkylenyl, aryloxyalkylenyl, hydroxyalkyl, alkylsulfonylalkylenyl, $-X'-Y-R_4$, and $-X'-R_5$; wherein X' is alkylene; Y is $-N(R_8)-C(O)-$, $-N(R_8)-S(O)_2-$, $-N(R_8)-S(O)_2-N(R_8)-$, $-N(R_8)-C(O)-N(R_8)-$, $-N(R_8)-C(O)-N(R_8)-C(O)-$,




; R₄ is hydrogen, alkyl, alkenyl, aryl, or heteroaryl, wherein alkyl and alkenyl are optionally substituted by aryl or aryloxy and wherein aryl is optionally substituted by one or more substituents selected from the group consisting of alkyl, alkoxy, cyano, and halogen; and R₅ is



60. (new) The compound or salt of claim 7 wherein R₂ and R" are each methyl.

61. (new) The compound or salt of claim 7 wherein R₂ and R" join together to form the ring system




, wherein R₁₁ is C₁₋₂ alkylene; A' is -CH₂-, -O-, or -N(-Q-R₄)-; Q is a bond or -C(O)-; and R₄ is alkyl or arylalkylenyl.

62. (new) The compound or salt of claim 7 wherein X is methylene.


63. (new) A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 7 in combination with a pharmaceutically acceptable carrier.

64. (new) A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound or salt of claim 7 to the animal.


65. (new) The compound or salt of claim 9 wherein R₁ is selected from the group consisting of alkyl, arylalkylenyl, aryloxyalkylenyl, hydroxyalkyl, alkylsulfonylalkylenyl, -X'-Y-R₄, and -X'-R₅; wherein X' is alkylene; Y is -N(R₈)-C(O)-, -N(R₈)-S(O)₂-, -N(R₈)-S(O)₂-N(R₈)-, -N(R₈)-C(O)-N(R₈)-, -N(R₈)-C(O)-N(R₈)-C(O)-,



; R₄ is hydrogen, alkyl, alkenyl, aryl, or heteroaryl, wherein alkyl and alkenyl are optionally substituted by aryl or aryloxy and wherein aryl is optionally substituted by one or more substituents selected from the group consisting of alkyl, alkoxy, cyano, and halogen; and R₅ is




66. (new) The compound or salt of claim 65 wherein R₁ is 2-methylpropyl, 2-hydroxy-2-methylpropyl, or -X'-Y-R₄; X' is ethylene, propylene, or butylene; Y is -NH-C(O)-, -NH-S(O)₂-, -NH-S(O)₂-N(R₈)-, -NH-C(O)-N(R₈)-, -NH-C(O)-NH-C(O)-, or



67. (new) The compound or salt of claim 9 wherein at least one of R" or R₂ is selected from the group consisting of alkyl, alkenyl, aryl, arylalkylenyl, heteroaryl, heteroarylalkylenyl, heterocyclyl, and heterocyclylalkylenyl, wherein the alkyl, alkenyl, aryl, arylalkylenyl, heteroaryl, heteroarylalkylenyl, heterocyclyl, and heterocyclylalkylenyl are optionally substituted.

68. (new) The compound or salt of claim 9 wherein R₂ and R" are each methyl.


69. (new) The compound or salt of claim 9 wherein R₂ and R" join together to form the ring system




, wherein R₁₁ is C₁₋₂ alkylene; A' is -CH₂-, -O-, or -N(-Q-R₄)-, Q is a bond or -C(O)-; and R₄ is alkyl or arylalkylenyl.

70. (new) The compound or salt of claim 9 wherein X is C₁₋₄ alkylene.


71. (new) The compound or salt of claim 70 wherein X is methylene.
72. (new) A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 9 in combination with a pharmaceutically acceptable carrier.
73. (new) A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound or salt of claim 9 to the animal.
74. (new) The compound or salt of claim 10 wherein R₁ is selected from the group consisting of alkyl, arylalkylenyl, aryloxyalkylenyl, hydroxyalkyl, alkylsulfonylalkylenyl, -X'-Y-R₄, and -X'-R₅; wherein X' is alkylene; Y is -N(R₈)-C(O)-, -N(R₈)-S(O)₂-, -N(R₈)-S(O)₂-N(R₈)-, -N(R₈)-C(O)-N(R₈)-, -N(R₈)-C(O)-N(R₈)-C(O)-,



; R₄ is hydrogen, alkyl, alkenyl, aryl, or heteroaryl, wherein alkyl and alkenyl are optionally substituted by aryl or aryloxy and wherein aryl is optionally substituted by one or more substituents selected from the group consisting of alkyl, alkoxy, cyano, and halogen; and R₅ is



75. (new) The compound or salt of claim 10 wherein R₂ and R" are each methyl.
76. (new) The compound or salt of claim 10 wherein R₂ and R" join together to form the ring system



, wherein R₁₁ is C₁₋₂ alkylene; A' is -CH₂-, -O-, or -N(-Q-R₄)-; Q is a bond or -C(O)-; and R₄ is alkyl or arylalkylenyl.

77. (new) The compound or salt of claim 10 wherein X is methylene.
78. (new) A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 10 in combination with a pharmaceutically acceptable carrier.
79. (new) A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound or salt of claim 10 to the animal.